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Introduction {#sec005}
============

Choosing the appropriate treatment for breast cancer (BC) patients with hormone-receptor (HR)-positive, HER2-negative, early disease can be a thorough and challenging process that requires the proper balancing of possible therapy benefits against the risk of potential side effects.\[[@pone.0228884.ref001],[@pone.0228884.ref002]\] In young women, decision-making is even more difficult as it is deeply influenced by age, resulting in the prescription of aggressive systemic therapy even in tumors with low-risk clinical features.\[[@pone.0228884.ref003]--[@pone.0228884.ref005]\] These intensive and prolonged systemic treatments often lead to considerable morbidity and significant psychosocial repercussions.\[[@pone.0228884.ref006]--[@pone.0228884.ref010]\]

Therefore, the medical community should strive to identify young patients who will not benefit from chemotherapy (CT) and could be treated with endocrine therapy (ET) alone. Gene expression profiling tests have been developed to provide clinicians with additional tools to aid them in the decision-making process, especially in situations where the benefit of adjuvant CT is equivocal.\[[@pone.0228884.ref001],[@pone.0228884.ref011],[@pone.0228884.ref012]\] These tests estimate the risk of distant recurrence in patients with HR-positive, HER2-negative BC with 0--3 positive lymph nodes. However, to date, clinical trials validating the use of genomic signatures in the clinical setting have included a limited number of young patients, thus restricting the extrapolation of results to this population.\[[@pone.0228884.ref013]\] Likewise, although some studies have evaluated the impact of these assays in oncological decision-making,\[[@pone.0228884.ref014]--[@pone.0228884.ref018]\] most of the assessed patients have been postmenopausal women and no study has focused exclusively in young women with BC.

EndoPredict, a multigene expression profiling test that predicts the likelihood of distant recurrence in patients with HR-positive, HER2-negative BC treated with adjuvant ET,\[[@pone.0228884.ref016]\] has been proven to be highly prognostic in node-negative or node-positive disease for early and late recurrence,\[[@pone.0228884.ref019]--[@pone.0228884.ref021]\] and also predicts benefit from adjuvant CT.\[[@pone.0228884.ref022]\] Additionally, it has been shown to be an independent prognostic parameter both in premenopausal and postmenopausal women treated with CT.\[[@pone.0228884.ref023]\]

The EPclin score, the final result of the EndoPredict test, takes into account molecular parameters and relevant clinical characteristics such as tumor size and nodal status, and can aid clinicians in the therapeutic decision-making process by classifying a patient as having a low- or high-risk of distant recurrence.\[[@pone.0228884.ref016],[@pone.0228884.ref017],[@pone.0228884.ref024]\] The aim of this study was to evaluate the change in therapeutic decision regarding adjuvant treatment in a cohort of young women with BC discussed by a multidisciplinary team, before and after the EndoPredict assay was performed.

Study design {#sec006}
============

Premenopausal patients with HR-positive, HER2-negative, T1-T2, and N0-N1 BC, who had not undergone systemic treatment, were eligible to participate in this study. Patients were classified as premenopausal if they had regular menses or serum FSH and estradiol levels in premenopausal ranges in case of amenorrhea \<12 months of duration or irregular menses during the last year. Women who met selection criteria were prospectively accrued between June 2016 and August 2018 at three specialized BC centers in Mexico: "Hospital San José" and "Hospital Zambrano Hellion" in Nuevo Leon, and "Fundación de Cáncer de Mama (FUCAM)" in Mexico City. EndoPredict tests were performed locally and results were available in a median of 18 calendar days. The study was approved by the institutional ethics and research committees of "Escuela de Medicina del Instituto Tecnológico y de Estudios Superiores de Monterrey": "Comité de Ética en Investigación" and "Comité de Investigación". Written consent was obtained from all patients.

Clinicopathological characteristics were recorded and each case was presented at each institution in a multidisciplinary tumor board comprised by medical oncologists, breast surgeons, gynecological oncologists, and radiation oncologists. Initial consensual therapeutic decisions were agreed on prior to EndoPredict results, and a second consensus was reached once results were available. The therapeutic recommendation was presented to the patient after this final decision.

The type of adjuvant treatment was decided according to an estimation of the risk of recurrence based on the clinical, pathological and molecular information of each particular case. More intensive or prolonged schemes were considered in high-risk patients, while less intensive or shorter ones were proposed in low-risk patients. Patients' medical records were reviewed at six-month follow-up to determine physicians' adherence to the tumor board recommendation. Patients' total follow-up and time to recurrence were calculated according to the time between accrual and last visit and the time between accrual and recurrence documentation, respectively.

The primary objective was to determine the change in decision-making by the tumor board regarding the use of adjuvant CT before and after disclosure of the EndoPredict result. Secondary objectives were to describe CT and ET recommended regimen changes before and after EndoPredict and to evaluate physicians' adherence with tumor board therapeutic consensus regarding CT use. Pearson chi-square was used to analyze low- or high-risk EPclin results between groups according to clinicopathological features such as age, nodal status, grade, and Ki67 levels. McNemar's test was used to evaluate the change in treatment recommendations before and after EndoPredict testing. The Mann-Whitney U test was used to compare the median EPclin score between low- and high-intensity CT and ET regimens.

For CT regimens, docetaxel + cyclophosphamide (TC) was considered a low-intensity treatment, while sequential anthracyclines + cyclophosphamide followed by taxanes regimen (AC-T) was classified as a high-intensity treatment. Regarding ET, tamoxifen for 5 years (y) and tamoxifen for 2-3y followed by an aromatase inhibitor (AI) until completing 5y were considered low-intensity regimens, while tamoxifen for 10y, ovarian function suppression (OFS) with a gonadotropin-releasing hormone (GnRH) analogue and either tamoxifen or an AI for 5y, were classified as high-intensity treatments.

Results {#sec007}
=======

Cohort description {#sec008}
------------------

A total of 99 consecutive premenopausal women were included in this study. Patient demographics and clinical characteristics are detailed in [Table 1](#pone.0228884.t001){ref-type="table"}. Median age at diagnosis was 43y, with 32.2% of patients aged ≤40y. The most frequent tumor size was pT2 (53.5%). Furthermore, 27.3% of patients had 1--3 positive lymph nodes including micrometastasis. Stages at diagnosis were IA, 38.4%; IB, 2%; IIA, 37.4%; and IIB, 22.2%. The most common tumor subtype was invasive ductal carcinoma (89%), followed by invasive lobular carcinoma (4%) and mucinous carcinoma (3%). Pathologic characteristics showed intermediate-grade tumors in 74% of patients and low Ki67 (\<20%) in half of the cohort (Tables [1](#pone.0228884.t001){ref-type="table"} and [2](#pone.0228884.t002){ref-type="table"}).

10.1371/journal.pone.0228884.t001

###### Patients' clinical and pathological characteristics.

![](pone.0228884.t001){#pone.0228884.t001g}

  Total number of cases               99 (100%)                   
  ----------------------------------- --------------------------- ------------
  **Patient age (years)**Median: 43   ≤35                         10 (10.1%)
  36--40                              22 (22.2%)                  
  41--45                              36 (36.4%)                  
  46--50                              28 (28.3%)                  
  \>50                                3 (3%)                      
  **Size (T)**                        pT1a                        1 (1%)
  pT1b                                10 (10.1%)                  
  pT1c                                35 (35.4%)                  
  pT2                                 53 (53.5%)                  
  **Lymph Nodes (N)**                 pN0                         71 (71.7%)
  pN1mic                              2 (1%)                      
  pN1                                 26 (26.3%)                  
  **Clinical Stage**                  IA                          38 (38.4%)
  IB                                  2 (2%)                      
  IIA                                 37 (37.4%)                  
  IIB                                 22 (22.2%)                  
  **Tumor subtype**                   Invasive ductal carcinoma   88 (89%)
  Invasive lobular carcinoma          4 (4%)                      
  Mucinous carcinoma                  3 (3%)                      
  Other                               3 (3%)                      
  Not available                       1 (1%)                      
  **Tumor grade**                     I                           11 (11.1%)
  II                                  73 (73.8%)                  
  III                                 11 (11.1%)                  
  Not available                       4 (4%)                      
  **Ki67**                            \<20%                       44 (44.4%)
  ≥20%                                44 (44.4%)                  
  Not available                       11 (11.1%)                  
  **Estrogen receptor**               Positive                    99 (100%)
  Negative                            0 (0%)                      
  **Progesterone receptor**           Positive                    89 (90%)
  Negative                            6 (6%)                      
  Not available                       4 (4%)                      
  **EPclin score**                    Low-risk                    46 (46.5%)
  High-risk                           53 (53.5%)                  

10.1371/journal.pone.0228884.t002

###### Patients' clinical and pathological characteristics by EPclin risk classification.

![](pone.0228884.t002){#pone.0228884.t002g}

  Total number of cases               Low risk 46 (100%)          High risk 53 (100%)   
  ----------------------------------- --------------------------- --------------------- ------------
  **Patient age (years)**Median: 43   ≤35                         5 (10.9%)             5 (9.4%)
  36--40                              6 (13%)                     16 (30.2%)            
  41--45                              19 (41.3%)                  17 (32.1%)            
  46--50                              14 (30.4%)                  14 (26.4%)            
  \>50                                2 (4.3%)                    1 (1.9%)              
  **Size (T)**                        pT1a                        1 (2.2%)              0 (0%)
  pT1b                                9 (19.6%)                   1 (1.9%)              
  pT1c                                22 (47.8%)                  13 (24.5%)            
  pT2                                 14 (30.4%)                  39 (73.6%)            
  **Lymph Nodes (N)**                 pN0                         44 (95.7%)            27 (50.9%)
  pN1mic                              0 (0%)                      2 (3.8%)              
  pN1                                 2 (4.3%)                    24 (45.3%)            
  **Clinical Stage**                  IA                          30 (65.2%)            8 (15.1%)
  IB                                  1 (2.2%)                    1 (1.9%)              
  IIA                                 13 (28.3)                   24 (45.3%)            
  IIB                                 2 (4.3%)                    20 (37.7%)            
  **Tumor subtype**                   Invasive ductal carcinoma   41 (89.1%)            47 (88.7%)
  Invasive lobular carcinoma          1 (2.2%)                    3 (5.7%)              
  Mucinous carcinoma                  3 (6.5%)                    0 (0%)                
  Other                               0 (0%)                      3 (5.7%)              
  Not available                       1 (2.2%)                    0 (0%)                
  **Tumor grade**                     I                           9 (19.6%)             2 (3.8%)
  II                                  34 (73.9%)                  39 (73.6%)            
  III                                 2 (4.3%)                    9 (17%)               
  Not available                       1 (2.2%)                    3 (5.7%)              
  **Ki67**                            \<20%                       26 (56.5%)            18 (34%)
  ≥20%                                16 (34.8%)                  28 (52.8%)            
  Not available                       4 (8.7%)                    7 (13.2%)             
  **Estrogen receptor**               Positive                    46 (100%)             53 (100%)
  Negative                            0 (0%)                      0 (0%)                
  **Progesterone receptor**           Positive                    43 (93.5%)            46 (86.8%)
  Negative                            1 (2.2%)                    5 (9.4%)              
  Not available                       2 (4.3%)                    2 (3.8%)              

Association of clinical and pathological factors with EndoPredict test result {#sec009}
-----------------------------------------------------------------------------

A total of 46 patients (46.5%) had a low-risk EPclin result. Notably, 38% of patients in the node-negative group had a high-risk result, while 8% with N1 status had a low-risk score (p \< .00001). When comparing results by age group, 34% of ≤40y-old patients had a low-risk EPclin, compared with 52% in older patients (p = .09). Tumor grade was significantly associated with the EPclin result, with 82% of low-grade tumors being categorized as low-risk, while 82% of high-grade tumors had a high-risk result (p = .0110). Intermediate-grade tumors were not predictive of EPclin results with a nearly 50--50 split between low- and high-risk categories. No significant association was found between EPclin and Ki67 levels, as 41% of low Ki67 tumors were classified as high-risk, while 36% of high Ki67 tumors had a low-risk score (p = .0548).

Impact of the EndoPredict test result on adjuvant treatment decision {#sec010}
--------------------------------------------------------------------

A change in CT decision was registered in 19/99 patients (19.2%; p = .066, McNemar test), with the greatest impact in CT de-escalation ([Table 3](#pone.0228884.t003){ref-type="table"} and [Fig 1](#pone.0228884.g001){ref-type="fig"}). Before having the test result, CT was recommended to 68% of patients; while post-test, CT was recommended in 59% of cases, resulting in a net reduction of CT recommendation of 9%. Net reduction was 13% in the N0 group (55% pre-test vs. 42% post-test; p = .066) and 0% in the N1 group (100% pre-test vs. 100% post-test; p = 0).

10.1371/journal.pone.0228884.t003

###### Pre- and post-EndoPredict chemotherapy consensus.

![](pone.0228884.t003){#pone.0228884.t003g}

  ---------------------- --------------- --------------------- ---------------------- -----------
                         **Post-test**                                                
  **Pre-test**                           **No chemotherapy**   **Yes chemotherapy**   **Total**
  **No chemotherapy**    27              **5**                 32                     
  **Yes chemotherapy**   **14**          53                    67                     
  **Total**              41              58 (9% reduction)     99                     
  ---------------------- --------------- --------------------- ---------------------- -----------

p = .066 for change in recommendation for chemotherapy

![Change in chemotherapy recommendation.](pone.0228884.g001){#pone.0228884.g001}

Overall tumor board treatment recommendation adherence to the EndoPredict result was 95% (recommending CT to patients with high-risk EPclin and abstaining to do so in patients with low-risk EPclin). The total population with a high-risk EPclin score was recommended to undergo CT, while 89% with a low-risk EPclin result was not. A total of five patients were recommended to undergo CT by the tumor board despite a low-risk EPclin result ([Table 4](#pone.0228884.t004){ref-type="table"}).

10.1371/journal.pone.0228884.t004

###### Low-risk EPclin patients recommended to undergo chemotherapy by the tumor board.

![](pone.0228884.t004){#pone.0228884.t004g}

  Age (y)   Tumor size (mm)   pT     pN    Stage   Grade          Ki67   EPclin   Reason for chemotherapy recommendation                                  Recommended chemotherapy regimen
  --------- ----------------- ------ ----- ------- -------------- ------ -------- ----------------------------------------------------------------------- ----------------------------------
  41        32                pT2    pN1   IIB     Low            5      2.8      Two positive nodes                                                      TC
  50        25                pT2    pN0   IIA     Intermediate   10     3.32     Tumor size and borderline EPclin[\*](#t004fn004){ref-type="table-fn"}   TC
  49        50                pT2    pN0   IIB     Intermediate   20     3        Tumor size and borderline Ki67 level                                    TC
  41        20                pT1c   pN0   IA      Low            NA     3.29     Borderline EPclin[\*](#t004fn004){ref-type="table-fn"}                  AC-T
  39        15                pT1c   pN1   IIA     Intermediate   5      3.2      Three positive nodes, two with extracapsular extension                  AC-T

**TC:** Docetaxel + Cyclophosphamide

**AC-T:** Anthracyclines + Cyclophosphamide followed by Taxanes

**NA:** Not available

\*Borderline EPclin refers to a result that was close to the 3.3 cutoff point for EPclin score--based risk stratification

Furthermore, 10/53 (19%) patients who were recommended to undergo CT both pre- and post-test had a change in the suggested CT regimen. The most frequent change was from TC to AC-T, in 6/10 cases (60%) ([Table 5](#pone.0228884.t005){ref-type="table"}).

10.1371/journal.pone.0228884.t005

###### Pre- and post-EndoPredict chemotherapy regimens.

![](pone.0228884.t005){#pone.0228884.t005g}

  Pre-EndoPredict regimen                                                                        Post-EndoPredict regimen                      Number of patients (n = 53)
  ---------------------------------------------------------------------------------------------- --------------------------------------------- -----------------------------
  Anthracyclines + Cyclophosphamide followed by Taxanes[\*\*](#t005fn004){ref-type="table-fn"}   AC-T[\*\*](#t005fn004){ref-type="table-fn"}   23 (43%)
  TC[\*](#t005fn003){ref-type="table-fn"}                                                        3 (6%)                                        
  Docetaxel + Cyclophosphamide[\*](#t005fn003){ref-type="table-fn"}                              TC[\*](#t005fn003){ref-type="table-fn"}       20 (38%)
  AC-T[\*\*](#t005fn004){ref-type="table-fn"}                                                    6 (11%)                                       
  Other                                                                                          AC-T[\*\*](#t005fn004){ref-type="table-fn"}   1 (2%)

**TC:** Docetaxel + Cyclophosphamide

**AC-T:** Anthracyclines + Cyclophosphamide followed by Taxanes

\*Low-intensity regimen

\*\*High-intensity regimen

Additionally, 20/99 (20.2%) patients had a change in the recommended ET regimen after the test result disclosure, with tamoxifen for 5y to tamoxifen for 10y being the most common treatment modification, seen in 9/20 cases (45%) ([Table 6](#pone.0228884.t006){ref-type="table"}).

10.1371/journal.pone.0228884.t006

###### Pre- and post-EndoPredict endocrine therapy regimens.

![](pone.0228884.t006){#pone.0228884.t006g}

  Pre-EndoPredict regimen                                                    Post-EndoPredict regimen                                                   Number of patients (n = 99)
  -------------------------------------------------------------------------- -------------------------------------------------------------------------- -----------------------------
  Tamoxifen 5y[\*](#t006fn003){ref-type="table-fn"}                          Tamoxifen 5y[\*](#t006fn003){ref-type="table-fn"}                          47 (48%)
  Tamoxifen 10y[\*\*](#t006fn004){ref-type="table-fn"}                       9 (9%)                                                                     
  Tamoxifen 2--3 y, then AI until 5 y[\*](#t006fn003){ref-type="table-fn"}   1 (1%)                                                                     
  Tamoxifen + GnRH analogue 5 y[\*\*](#t006fn004){ref-type="table-fn"}       2 (2%)                                                                     
  AI + GnRH analogue 5y[\*\*](#t006fn004){ref-type="table-fn"}               3 (3%)                                                                     
  Tamoxifen 10y[\*\*](#t006fn004){ref-type="table-fn"}                       Tamoxifen 10y[\*\*](#t006fn004){ref-type="table-fn"}                       12 (12%)
  Tamoxifen 5y[\*](#t006fn003){ref-type="table-fn"}                          2 (2%)                                                                     
  Tamoxifen 2--3 y, then AI until 5 y[\*](#t006fn003){ref-type="table-fn"}   1 (1%)                                                                     
  Tamoxifen 2--3 y, then AI until 5 y[\*](#t006fn003){ref-type="table-fn"}   Tamoxifen 2--3 y, then AI until 5 y[\*](#t006fn003){ref-type="table-fn"}   9 (9%)
  Tamoxifen 5y[\*](#t006fn003){ref-type="table-fn"}                          1 (1%)                                                                     
  AI + GnRH analogue 5y[\*\*](#t006fn004){ref-type="table-fn"}               AI + GnRH analogue 5y[\*\*](#t006fn004){ref-type="table-fn"}               9 (9%)
  Tamoxifen 5y[\*](#t006fn003){ref-type="table-fn"}                          1 (1%)                                                                     
  Tamoxifen + GnRH analogue 5y[\*\*](#t006fn004){ref-type="table-fn"}        Tamoxifen + GnRH analogue 5y[\*\*](#t006fn004){ref-type="table-fn"}        2 (2%)

**y:** years

**AI:** aromatase inhibitor

\*Low-intensity regimen

\*\*High-intensity regimen

A significant difference was found in the median EPclin score between patients with a low- vs. high-intensity CT regimen recommendation (3.7 \[1.3 SD\] vs 4 \[1.2 SD\], p = 0.049) ([Fig 2](#pone.0228884.g002){ref-type="fig"}).

![Chemotherapy regimen intensity according to EPclin.](pone.0228884.g002){#pone.0228884.g002}

Similarly, there was also a significant difference in the median EPclin score between patients with a low- vs. high-intensity ET regimen recommendation (3 \[1.0 SD\] vs 3.9 \[1.4 SD\], p = 0.0001) ([Fig 3](#pone.0228884.g003){ref-type="fig"}).

![Endocrine therapy regimen intensity according to EPclin.](pone.0228884.g003){#pone.0228884.g003}

Regarding attending physicians' adherence to the tumor board post-test recommendation, the suggested treatment regimen was followed in 98% of cases. In two patients, CT was not recommended by the tumor board due to the patients' low-risk clinical features and a low-risk EPclin result; however, treatment was ultimately prescribed by their attending physician, who did not attend the BC multidisciplinary tumor board. In both cases, the reason for recommending CT was not documented in the patients' medical files.

Final treatment adherence to EPclin result was 93% (administering CT in high-risk EPclin and no CT in low-risk EPclin).

A comparison between CT recommendation pre- and post-EPclin result, as well as the actual treatment prescribed to patients by their treating physicians is shown in [Fig 4](#pone.0228884.g004){ref-type="fig"}.

![Chemotherapy recommendation pre- vs. post-EndoPredict results and actual chemotherapy prescription by treating physician.](pone.0228884.g004){#pone.0228884.g004}

Follow-up {#sec011}
---------

Patients' median follow-up time was 22.9 months. During this period, four patients presented disease recurrence, with follow-up times to recurrence of 11.7, 14.3, 36.9, and 42.4 months. Two of these patients were classified as low-risk by the EndoPredict test and had local recurrences. Of the other two patients, classified as high-risk, one had a local recurrence and the other one had a distant recurrence. All patients were alive up to their last follow-up visit.

Discussion {#sec012}
==========

This is the first study that specifically evaluates the EndoPredict assay effect in decision-making in a premenopausal BC patient cohort. Overall, we reported a higher proportion of high-risk patients in this study (54%) when compared to the previous validation trials ABCSG 6&8 and TransATAC, where 37% and 41.2% of patients had a high-risk result, respectively.\[[@pone.0228884.ref024],[@pone.0228884.ref025]\] These findings might reflect the higher baseline risk of our younger patients, compared to the previously mentioned trials, which only included postmenopausal patients.

Furthermore, we observed a clinically significant impact on treatment de-escalation with a 9% absolute reduction in CT recommendation. This impact is smaller than that reported in three other decision impact trials, where absolute reduction in CT recommendation ranged from 13.1% to 33%.\[[@pone.0228884.ref015]--[@pone.0228884.ref017]\] The reported lower overall change in treatment decision could be explained by a reliable clinical judgment by tumor boards held at academic centers for identifying high-risk pre-menopausal patients based on clinicopathological variables alone. Nevertheless, our physicians may have overtreated patients if therapeutic decisions relied on clinical characteristics only, as we found a substantial discordance between nodal status, tumor grade and Ki67 levels compared to EPclin results, which justifies the use of gene expression panels.

Interestingly, an impact on the CT and ET regimen was also observed when comparing the pre- and post-test tumor board consensus. While there is no data supporting the change in the CT and ET regimen based on gene expression assay results, there is a rationale for administering less intense regimens in patients with a low-risk EPclin, especially when considering the high prognostic performance of the EndoPredict assay for early and late recurrence in both node-negative and node-positive disease.\[[@pone.0228884.ref019]--[@pone.0228884.ref021],[@pone.0228884.ref025]\]

Recently, 15-y long-term outcome data showed that patients with a low-risk EPclin score treated with 5y of ET alone had a very low 5-15-y risk of distant recurrence, with a distant recurrence-free rate of 95.7%. Therefore, extension of ET up to 10y might not be necessary in this subgroup.\[[@pone.0228884.ref020]\] This supports the less intense ET in our patients.

Remarkably, tumor board treatment recommendation according to the EndoPredict test result (recommending CT to patients with high-risk EPclin and abstaining to do so in patients with low-risk EPclin) and final treatment adherence to the test score reached 95% and 93%, respectively. Our treatment adherence was even higher than the 85% reported previously by Fallowfield et al.\[[@pone.0228884.ref014]\] Additionally, to our knowledge, this is the first study that describes attending physicians' adherence to the tumor board post-test recommendation.

One of the strengths of this study is the prospective evaluation of a well-defined population of patients and recruitment from three different BC centers in Mexico. Furthermore, it is focused exclusively in premenopausal BC patients and describes how the EPclin score impacts the type of recommended CT or ET regimen as well as adding to the overall information of the performance of the EndoPredict assay.

Conclusion {#sec013}
==========

Overall, the EndoPredict assay's greatest impact was aiding in the discrimination of premenopausal patients that would not benefit from CT. While the overall CT reduction in our study was lower than that in previously published trials, it is still clinically relevant as it allowed several young patients, typically regarded as high-risk, to avoid unnecessary adverse effects that could significantly affect their quality of life.

The EndoPredict test successfully assisted the clinical decision-making process in premenopausal patients, with a high rate of therapeutic adherence and a clinically significant change in overall decision-making.

Supporting information {#sec014}
======================

###### Research protocol complete database.

(XLSX)

###### 

Click here for additional data file.
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Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: In this manuscript, the authors come up with EndoPredict assay in a prospective decision impact study of Mexican premenopausal breast cancer patients to change therapeutic management. The validity of EndoPredict test to assist the clinical decision-making process in premenopausal patients deserve deeper discussion. It would be helpful to observe the study longer for patient outcome and expand the sample size. Besides, the analysis of post- EndoPredict results should be illustrated more detailedly.

Reviewer \#2: Villareal-Garza and co-authors present an interesting decision impact study of EndoPredict in specifically younger women. The manuscript is well written and presents interesting findings on pre- versus post-treatment deicision making in premenopausal women. As the authors state most validation and decision-impact studies have been performed in older, postmenopausal women and therefore their results is relevant for the clinical decision making in younger women.

A few minor points might improve the manuscript:

1\. It would be helpful to add EPclin scores (means) or percentage low/high risk to Table 1 so the reader has all the information in one place.

2\. Table 2 would benefit from adding percentage change. I am aware that this is stated in the text but with added percentages the reader has the full picture just looking at the table.

3\. Perhaps a Figure would make Table 2 even more appealing to readers showing the changes in treatment between pre- and post EndoPredict testing.

4\. Table 4 and 5 again please add percentages as number scan be deceiving.

5\. For Table 5, I suggest putting the low intensity ET regimes, tamoxifen 5y and tamoxifen 2-3y then AI, underneath each other or to make it very clear in the table which are the low versus high intensity regimens.

6\. Figures 1 and 2: I suggest showing box plots for the EPclin scores with 95% CI so it is clear to the reader what the means are and it is visually easier to see that there is a difference.

Reviewer \#3: This paper evaluates the change in adjuvant therapeutic decision in a series of 99 premenopausal women with hormone receptor-positive/HER2-negative breast cancer before and after EndoPredict testing. A change in chemotherapy decision was recorded in around 19% of patients, with the greatest impact in de-escalation, with a net reduction of 9% in chemothepary recommendation. After EPclin result, a change in chemotherapy or endocrine therapy was recommended in 19% and 20% of cases, respectively. Aditionally, adherence to tumor board recommendation with the EndoPredict result was also analyzed. Overall, this is an interesting study that specifically evaluates EndoPredict result effect in decision-making in a cohort or premenopausal women with early breast cancer.

Comments.

Study design. Elegible participants (line 73). Specific selection criteria should be detailed in the text.

Line 83. The authors indicate that consensual therapeutic decisions before and after EndoPredict results were registered. However, the criteria followed when deciding the type of adjuvant treatment in each case (chemotherapy or endocrine therapy) are not specified. Please, indicate this criteria in the text.

I assume that EndoPredict test was performed centrally and not in each of the hospitals participating in the study. If so, please include this information in the text. Information regarding the time between the test request and the result of the test should also be detailed. Did the multidisciplinary tumor board make a provisional treatment decision-either to have or to omit adjuvant chemotherapy- in these cases? Did patients participate in decision making?

Cohort description (line 102). Tumor subtype (histology) should be detailed in the text/table 1. Please, also include the distribution of cases regarding estrogen receptor positivity (should be 100%!) and, more interesting as is usual more heterogeneous than estrogen receptor, progesterone receptor positivity/negativity.

The inclusion of a patient with a pT1a tumor is striking. Could you please give explain why this patient was included in the series (high tumor grade, lymph node mets...)?

Was the molecular phenotype of the tumors (mainly, luminal A and luminal B) taken into account when deciding to perform the Endopredict test?

A table showing the clinical and pathological characteristics of the patients classified as high- or low-risk by EPclin score should be included in the text.

Table 3. This is a very interesting table. Please indicate what do you mean by 'borderline' EPclin. In patient 4 (41 y) tumor size is not available although it is indicated that corresponds to a pT1c stage. Could you please clarify this point? In the same patient, Ki67 was not available. Considering the importance of Ki67 in such cases, please indicate the reason why this data is not available. I suggest, if possible, to perform the technique again.

There are minor grammatical errors in the text that should be reviewed and corrected, e.g., line 55, have instead of has; line 153, did instead of does.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Response to Reviewers

Reviewer \#1

In this manuscript, the authors come up with EndoPredict assay in a prospective decision impact study of Mexican premenopausal breast cancer patients to change therapeutic management. The validity of EndoPredict test to assist the clinical decision-making process in premenopausal patients deserve deeper discussion. It would be helpful to observe the study longer for patient outcome and expand the sample size. Besides, the analysis of post- EndoPredict results should be illustrated more detailedly.

\- Thank you for your observations. Median follow-up time was 22.9 months. During this period, four patients presented disease recurrence, with follow-up times to recurrence of 11.7, 14.3, 36.9, and 42.4 months. Two of these patients were classified as low-risk by the EndoPredict test and had local recurrences. Of the other two patients, classified as high-risk, one had a local recurrence and the other one had a distant recurrence. All patients were alive up to their last follow-up visit (lines 178-182).

\- Regarding the suggestion of expanding the sample size, post-hoc extension of this prospective study which achieved its primary objective would be difficult to justify and to execute as it would need additional non-available budget and 1-2 extra years. Therefore, it is not feasible for us to do it. Hopefully, the scientific and medical community will find our results focused on an understudied population of premenopausal women valuable and significant.

\- A new Table 2 and Figures 1, 2 and 3 have been added and will contribute to better illustrate the EndoPredict results.

o In Table 2, we described patients' clinical and pathological characteristics according to their EPclin risk.

o In Figure 1, we graphed the percentage of change in chemotherapy recommendation.

o In Figures 2 and 3, we included box plots showing the chemotherapy and endocrine therapy regimens' intensity according to the EPclin scores, as suggested by Reviewer \#2.

Reviewer \#2

Villareal-Garza and co-authors present an interesting decision impact study of EndoPredict in specifically younger women. The manuscript is well written and presents interesting findings on pre- versus post-treatment decision making in premenopausal women. As the authors state most validation and decision-impact studies have been performed in older, postmenopausal women and therefore their results are relevant for the clinical decision making in younger women.

A few minor points might improve the manuscript:

1\. It would be helpful to add EPclin scores (means) or percentage low/high risk to Table 1 so the reader has all the information in one place.

\- Thank you for this suggestion, it has been added to Table 1.

2\. Table 2 would benefit from adding percentage change. I am aware that this is stated in the text but with added percentages the reader has the full picture just looking at the table.

\- We have added the percentage of change in chemotherapy recommendation to Table 3 (which was previously Table 2).

3\. Perhaps a Figure would make Table 2 even more appealing to readers showing the changes in treatment between pre- and post EndoPredict testing.

\- The data of this table has been depicted in a new Figure 1.

4\. Table 4 and 5 again please add percentages as number scan be deceiving.

\- Thank you for your observation, we have included the corresponding percentages to Tables 5 and 6 (which were previously Tables 4 and 5).

5\. For Table 5, I suggest putting the low intensity ET regimes, tamoxifen 5y and tamoxifen 2-3y then AI, underneath each other or to make it very clear in the table which are the low versus high intensity regimens.

\- We have now specified which are low- and high-intensity regimens in Table 6 (which was previously Table 5).

6\. Figures 1 and 2: I suggest showing box plots for the EPclin scores with 95% CI so it is clear to the reader what the means are and it is visually easier to see that there is a difference.

\- Following your suggestion, Figures 2 and 3 (which were previously Figures 1 and 2) now show box plots.

Reviewer \#3

Study design. Eligible participants (line 73). Specific selection criteria should be detailed in the text.

\- Thank you for this observation. Selection criteria are now detailed in Study design (lines 73-77): Premenopausal patients with HR-positive, HER2-negative, T1-T2, and N0-N1 BC, who had not undergone systemic treatment, were eligible to participate in this study. Patients were classified as premenopausal if they had regular menses or serum FSH and estradiol levels in premenopausal ranges in case of amenorrhea \<12 months of duration or irregular menses during the last year.

Line 83. The authors indicate that consensual therapeutic decisions before and after EndoPredict results were registered. However, the criteria followed when deciding the type of adjuvant treatment in each case (chemotherapy or endocrine therapy) are not specified. Please, indicate these criteria in the text.

\- These criteria have been included in the text (lines 88-91): The type of adjuvant treatment was decided according to an estimation of the risk of recurrence based on the clinical, pathological and molecular information of each particular case. More intensive or prolonged schemes were considered in high-risk patients, while less intensive or shorter ones were proposed in low-risk patients.

I assume that EndoPredict test was performed centrally and not in each of the hospitals participating in the study. If so, please include this information in the text. Information regarding the time between the test request and the result of the test should also be detailed.

\- EndoPredict tests were performed locally and results were available in a median of 18 calendar days (line 80).

Did the multidisciplinary tumor board make a provisional treatment decision-either to have or to omit adjuvant chemotherapy- in these cases?

\- Initial consensual therapeutic decisions were agreed on prior to EndoPredict results, and a second consensus was reached once results were available. The therapeutic recommendation was presented to the patient after this final decision (lines 85-87).

Did patients participate in decision making?

\- Patients did not participate in the decision-making process.

Cohort description (line 102). Tumor subtype (histology) should be detailed in the text/table 1. Please, also include the distribution of cases regarding estrogen receptor positivity (should be 100%!) and, more interesting as is usual more heterogeneous than estrogen receptor, progesterone receptor positivity/negativity.

\- Thank you for your suggestions. Tumor subtypes and estrogen and progesterone receptor positivity, with 1% cutoff, are now included in Tables 1 and 2.

The inclusion of a patient with a pT1a tumor is striking. Could you please give explain why this patient was included in the series (high tumor grade, lymph node mets...)?

\- This patient was included because she met inclusion criteria given that she had a hormone receptor-positive, HER2-negative, T1-T2, and N0-N1 breast cancer, and had not undergone systemic treatment. Moreover, her tumor was of intermediate grade and had lymphovascular invasion, which posed doubts regarding her prognosis and made the genomic test result valuable for treatment recommendations.

Was the molecular phenotype of the tumors (mainly, luminal A and luminal B) taken into account when deciding to perform the Endopredict test?

\- This data was not considered, only inclusion criteria were taken into account. However, the classification of Luminal A-like and Luminal B-like was considered for the pre- and post-test therapeutic decisions.

A table showing the clinical and pathological characteristics of the patients classified as high- or low-risk by EPclin score should be included in the text.

\- This information has been included in a new Table 2.

Table 3. This is a very interesting table. Please indicate what do you mean by 'borderline' EPclin.

\- By borderline EPclin, we refer to two results (3.29 and 3.32) that were very close to the cutoff point that divides the low- and high-risk categories (3.3). This clarification has been added to Table 4 (which was previously Table 3).

In patient 4 (41 y) tumor size is not available although it is indicated that corresponds to a pT1c stage. Could you please clarify this point?

\- Upon this commentary, we checked this patient's medical record again and recovered her tumor size, which was 20 mm and indeed corresponded to a pT1c stage. This has been added to Table 4 (which was previously Table 3).

In the same patient, Ki67 was not available. Considering the importance of Ki67 in such cases, please indicate the reason why this data is not available. I suggest, if possible, to perform the technique again.

\- This patient came to our clinic after her surgery, the immunohistochemistry was performed elsewhere, and the Ki67 result was not executed there. The Ki67 testing cannot be performed again given that her biological sample is no longer available in the pathology repository.

There are minor grammatical errors in the text that should be reviewed and corrected, e.g., line 55, have instead of has; line 153, did instead of does.

\- Thank you for this observation. We have proofread the manuscript again and corrected these and a few other errors.
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